Clinically, C/EBPα mutations occur in approximately 10% of AML cases, and leading to expression of N-terminally truncated C/EBPα-p30 protein, which lacks the first 119 amino acids (Fig. 3a)3,4. This evidence concerns the gene CEBPA and acute myeloid leukemia.